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ABSTRACT  
Background: Randomized clinical trials of combination antiretroviral therapy (cART) inform 
the use of specific antiretrovirals (ARV) and their combination for optimizing therapeutic 
efficacy. It is critical that patients have access to and receive the most appropriate first-line 
treatment.  
Objective: To examine factors that impact receiving initial guideline-recommended cART 
within a cohort of commercially insured patients in the United States (US) 
Research Design: A population based cohort study.  
Data Sources: A secondary administrative insurance claims database.  
Subjects: Employed, commercially insured individuals with HIV who were continuously 
eligible for insurance coverage from January 2007 through December 2009 and received a new 
ARV prescription.  
Measures: The primary outcome was defined as an initial claim for a prescription containing 
recommended cART consisting of two nucleoside reverse transcriptase inhibitors and either a 
non-nucleoside reverse transcriptase inhibitor, protease inhibitor or an integrase strand transfer 
inhibitor. Modified Poisson adjusted multivariable models including patient demographic and 
provider characteristics evaluated predictors of receiving recommended cART. 
Results: Of the 2,115 patients with a new ARV claim, 59% were white and 71% were male with 
a median age of 42 years (Interquartile Range: 35-49). Overall, 76% of the population received 
recommended cART. Receiving care from an infectious disease specialist was the strongest 
predictor of receiving recommended cART (Risk Ratio: 1.37, 95% Confidence Interval (CI): 
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1.30, 1.43). Men, those with less education, younger individuals, and no comorbidities were also 
more likely to receive recommended cART (p<0.01).   
Conclusions: Many HIV-infected patients that are in clinical care are not prescribed 
recommended cART. Increased communication and training of healthcare providers is necessary 
to insure patients receive a durable first-line regimen. 
Keywords:  guideline recommended cART, provider specialty 
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INTRODUCTION  
Human Immunodeficiency Virus (HIV) is a retrovirus that infects CD4 cells, destroying 
the immune system and eventually making an infected individual prone to opportunistic 
infections. The virus is known to spread through blood, sexual fluids, and breast milk.1 Though 
the first cases of Acquired Immunodeficiency Syndrome (AIDS) were diagnosed in the 1970’s, 
the causal relationship between the HIV and AIDS was not established until 1984.2 Since its 
discovery, the HIV epidemic had killed 700,000 people within the United States and 39 million 
people around the globe.3 However, incidence began decreasing in 1996 due to the introduction 
of combined antiretroviral therapy which resulted in a significant reduction in HIV-related 
mortality rates. Public health efforts, focusing on prevention and education, have also 
contributed to the fact that in 2013, incidence was declining in 39 countries.4  Though cases in 
the developing world represent roughly two thirds of current HIV disease burden, industrialized 
nations have improved HIV care; therefore, HIV is transitioning to a chronic disease state in 
regions such as North America and Europe due to increased life expectancy from antiretroviral 
medications.5   
The FDA has currently approved 37 antiretroviral (ARV) medications consisting of 5 general 
groups which each target a different part of the virus’s life cycle. First, Nucleoside/Nucleotide 
Reverse Transcriptase Inhibitors (NRTIs) are the backbone of HIV therapy and target the virus’s 
replication within the cell. Non-Nucleotide Reverse Transcriptase Inhibitors, like NRTIs inhibit 
the reverse transcriptase enzyme and prevent replication. However, NNRTIs do not mimic 
natural substrates and bind to a different active site.6 Protease Inhibitors, which are often boosted 
by addition of ritonavir, prevent the maturation of the in virus into its fully infectious form. 
Integrase Strand Transfer Inhibitors (ISTIs) prevent viral DNA from being integrated into host 
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cell DNA during the replication process. Finally, both co-receptor antagonists and fusion 
inhibitors prevent entry of the virus into the host cell.7 Due to their differing mechanisms, these 
medications are used in combination to reduce a patient’s viral load and prevent progression of 
the disease as well as to reduce the transmission of the virus to others.   
As the number of HIV medications has increased, prescribing of these medications has become 
increasing complex due to both the number of options and the ability to individualize therapy. 8 
This can lead to inappropriate prescribing patterns. Randomized clinical trials of combination 
antiretroviral therapy (cART) have informed the use of specific ARVs and their combination for 
optimizing therapeutic efficacy. Therefore, since 1998, the United States (US) Department for 
Health and Human Services (DHHS) has published evidence-based guidelines for treatment of 
HIV-infected patients using ARVs in order to provide guidance to prescribers.9 Over time, these 
guidelines have been systematically updated, leading to significant changes in prescribing 
recommendations over the last 16 years. For example, in May 2006, the DHHS Panel 
recommended that “an initial regimen contain two nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTI) + a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-
boosted or unboosted protease inhibitor (PI)”.10 Updates were published in December 2007 and 
January 2008.11  
Despite continuous advances in the diagnosis and treatment of individuals living with HIV, there 
are still an estimated 50,000 incident cases of HIV each year in the United States.12 The DHHS 
guidelines make it clear that certain regimens should be avoided due to toxicity, resistance 
potential, drug interactions, and reduced efficacy and studies have shown improved outcomes for 
patients who use guideline-recommended treatment regimens.10,13  Furthermore, first-line ARV 
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treatment currently represents an estimated 39.4% of the total cost of care for an HIV-infected 
patient. Therefore, it is important to assess the receipt of ARV regimens that follow national 
guidelines in order to ensure a high quality of care for HIV-infected patients and to prevent 
incident cases of HIV.14 
Several studies have evaluated concordance with practice guidelines both in the US and abroad 
through small cohorts or public insurance claims data.13,15-21 However, most US studies analyzed 
prescribing practices before 2006, and very few studies have examined private insurance data to 
evaluate DHHS guideline adherence. Using a private insurance claims database is advantageous 
as it provides a broader understanding of how guidelines are being implemented in the general 
population of the US. Also, a reassessment of predictive factors of appropriate care is important 
in order to understand the evolution and status of treatment in the HIV-infected patient 
population. Therefore, this study evaluates factors associated with appropriate initiation of 
guideline-recommended ARV treatment among HIV-infected patients with private insurance 
from 2007 to 2009.   
METHODS 
Study Design:  
We constructed a cohort of HIV-infected patients using a secondary administrative claims 
database of employed, commercially insured individuals with dependents who were continuously 
eligible for insurance coverage from January 2007 through December 2009.  This nationally 
representative database contains information such as enrollment data, inpatient/outpatient 
insurance claims, diagnosis codes, and claims for prescription medications that were covered by 
the insurance provider. Among HIV-infected patients that were incident users of ARVs, we 
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examined factors that predicted each patient’s likelihood of receiving ARVs that are part of 
guideline recommended cART compared to those that received ARVs that were not part of a 
guideline recommended treatment regimen. 
Study Population 
Our study population included commercially insured patients living with HIV that were at least 
18 years of age and were incident users of common first line ARVs. Patients were considered to 
be HIV positive if they had a claim containing an International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) diagnosis code indicative of HIV (042) or a 
pharmacy claim containing a National Drug Code (NDC) for an FDA approved ARV.  Incident 
users of ARVs were defined as patients who had a claim for at least one ARV following a period 
of 180 days without an ARV claim. Regimens were defined as a set of ARVs that were filled on 
the same day and ordered sequentially.  Initial regimens were defined as the initial combination 
of medications that a patient filled together for at least 7 days. Patients with only one regimen for 
less than 7 days were excluded from the analysis. Finally, since certain Nucleoside Reverse 
Transcriptase Inhibitors (NRTIs) can be used as monotherapy or dual therapy to treat Hepatitis B 
infections, patients were excluded if their records contained an ICD-9 Code for Hepatitis B 
(070.XX) but did not contain an ICD-9 Code for HIV or if their prescription records contained 
Epivir HBV and they did not have an HIV diagnosis code.  
Study outcomes and measurements 
Initial ARVs were categorized by the number of ARVs as well as the medication classes that 
comprised each regimen, according to the DHHS guidelines.  Monotherapy and dual therapy 
9 
 
were defined as a regimen containing one or two medications, respectively. Patients taking three 
NRTIs simultaneously were categorized as Triple NRTI therapy. Regimens with two NRTIs as a 
base were categorized by the third drug in the regimen: Non-nucleoside reverse transcriptase 
inhibitor (NNRTI), protease inhibitor (PI), ritonavir boosted protease inhibitor (Boosted PI), 
Integrase Strand Transfer Inhibitor (ISTI).  
Using the DHHS guidelines from May 2006 to January 2008, we classified regimens into two 
categories, guideline recommended and non-guideline recommended. Monotherapy, dual 
therapy, and triple NRTI therapy were all considered non-guideline recommended regimens. 
NNRTI, PI, Boosted PI and ISTI regimens were classified as guideline recommended regimens. 
If a regimen contained multiple drugs from multiple classes on top of a normal NRTI base, they 
were categorized as guideline recommended.  All other ARV combinations were considered to 
be non-guideline recommended. (Table 1) Finally, if a patient was taking a coformulated 
medication, we considered the chemical entities that were contained in the coformulation and 
classified the regimens accordingly.  
Based on previous studies, we considered a priori a list of potential predictors of guideline 
recommended cART as initial therapy. These factors were assessed in the claims 180 days prior 
to initiating ARV treatment and included available socio-demographic variables (age, race, sex, 
education) as well as covariates shown to be related to a patients overall health condition 
(i.e.frailty)22, including the presence of comorbidities represented by the Charlson comorbidity 
index23 and overall number of healthcare claims (healthcare utilization). As we hypothesized that 
provider specialty and location may impact the type of regimen received, we examined whether a 
patient had any claims associated with an infectious disease (ID) specialist and individual’s 
geographic location (Northeast, Southeast, Midwest, Rocky, Pacific). To examine trends in ARV 
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prescribing we assessed changes in the types of regimens received by calendar year. We also 
included year of initiation in bivariable and multivariable analyses to identify changes in ARV 
receipt over the study period.  
The Predictive Model 
The model used in this study is primarily predictive. Therefore, it takes known information about 
a population and predicts the incidence of an outcome based on these factors, whether or not they 
are causally related to the outcome. This serves a different purpose from epidemiologic models 
which are used to explain an outcome using known causal associations and represent a picture of 
elements that lead to a disease or outcome. Predictive models have many uses in setting up 
randomized clinical trials, establishing screening guidelines, and identifying high risk groups in 
order to increase efficiency in interventions with limited resources. 24-27 
Statistical Analysis 
Unadjusted bivariate analysis using χ2   and t-test or Mann-Whitney U test statistics, where 
appropriate, were performed. To examine factors that predicted the receipt of guideline-
recommended initial cART regimens, we used a generalized linear model with a modified 
Poisson distribution, log and identity links for risk ratios (RR) and risk differences (RD) 
respectively, and robust variance to generate 95% confidence intervals (CI).28 A backwards 
elimination approach was used to identify a final predictive model. A priori statistical 
significance level was set at alpha = 0.05. In order to assess the model fit, we calculated the 
probabilities of receiving a preferred or non-preferred regimen based on the final model. These 
probabilities were then compared to the actual outcomes through logistic regression in order to 
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output an ROC curve and calculate a concordance (c) statistic for discriminative ability. All 
analyses were performed using SAS statistical software v. 9.3 (Cary, NC). This study was 
funded, in part, by the National Institutes of Health grant numbers K12 DA035150 and 
UL1TR000117 through the availability of data resources and salary support.  
RESULTS 
Of the 10,153 patients identified as HIV positive in the claims data, we identified 2,316 patients 
that had an incident medical claim for at least one ARV between January 1, 2007 and December 
31, 2009. After excluding patients with only one regimen for less than 7 days (N=35), those with 
an HIV diagnosis code with a diagnosis code for hepatitis B (N=113) or a claim containing 
Epivir HBV without an HIV diagnosis code (N=53), there were 2,115 patients with incident 
ARV use included in the analysis. Of these, 1,613 (76%) received guideline recommended 
cART.  Compared to patients receiving recommended cART, those that did not receive guideline 
recommended ARV therapy were more likely to be female, black, have at least a high school 
education and less likely to have a claim associated with an ID specialist in bivariable analysis. 
(Table 2)  
In multivariable analysis, provider status, sex, education, comorbidity status, and age were 
statistically significant while healthcare utilization, year of service, race and geography were not 
statistically significantly associated with receiving guideline recommended cART.  Our 
predictive model resulted in a c statistic of 0.74. Patients having at least one claim associated 
with an ID specialist was the strongest predictor of recommended cART, with these individuals 
having 1.37 times (95% CI 1.30,1.43) the likelihood of receiving recommended cART than 
patients that did not have a claim associated with an ID specialist. This corresponds to a risk 
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difference of 0.27 (95% CI: 0.23,0.30). Therefore, for every 3.7 patients who have a claim 
associated with an ID specialist, 1 patient received a guideline recommended regimen who 
otherwise would have received a non-guideline recommended regimen. Males were also more 
likely to receive guideline recommended cART than women [RR: 1.24 (95% CI:  1.15,1.33]. 
Patients who had more than a high school education, older patients as well as those with a 
Charlson comorbidity index > 1 were less likely to receive recommended cART. (Table 3)  
Prescribing trends were mostly consistent from 2007 to 2009 with the exception of prescription 
of boosted PIs and monotherapies. Monotherapies increased from 6.6% of all initial antiretroviral 
regimens in 2007 to 16.4% in 2009. Conversely, boosted PIs declined from 26.9% of regimens in 
2007 to 16.2% of regimens in 2009.  Finally, in multivariable analysis, year of initiation was not 
associated with guideline recommended treatment.   
 
DISCUSSION  
We found that among commercially insured HIV-infected patients initiating ARV therapy 
between 2007 and 2009, 24% did not receive guideline recommended treatment. Furthermore, 
gender, education, comorbidities, and involvement of an ID specialist were all associated with 
the receipt of guideline-recommended cART regimens.  Indeed, this is not the first study of 
guideline adherence to cART. Previous researchers have demonstrated the considerable 
variability in adoption of HIV prescribing guidelines both in the US and other countries. In 
Brazil, for example, a study found that only 2% of patients were receiving inappropriate 
regimens according to national guidelines, but a much larger percent were using suboptimal 
regimens.20 In the US, guideline adherence has been inconsistent. Mann et al. noted a lack of 
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physician adherence to guidelines involving the patient counseling and initial prescription of 
ARV therapy in 2000.19 Conversely, Hirschhorn et al. found that 78% of women and 82% of 
men in Ryan-White funded facilities were receiving recommended Highly Active Antiretroviral 
Therapy (HAART) between 1999 and 2001.29 Fleishman et al. noted an increase in the receipt of 
broadly defined ARV therapy from 60% of eligible patients within the HIV Research Network in 
2002 to 81% in 2008. 30 Notably, most of these studies were completed in patients with public 
insurance or at the institutional level, with the majority completed before 2006. This study 
provides an important contribution to the current evidence as it evaluates the initial cART receipt 
in commercially insured patients which allows for the understanding of broader trends in HIV 
medication use for patients who are not seen public hospitals or large academic research centers. 
Our results demonstrate sex disparities in the receipt of guideline recommended initial cART in 
commercially insured patients.  These results are contiguous with earlier studies which have 
indicated that sex was an important indicator in determining whether or not a patient would 
receive appropriate treatment.13,15,16,31-33  Results from two cross-sectional studies of the HIV 
Research Network spanning from 2001 to 2008 found that females were consistently less likely 
to receive HAART than males patients.30,32  In a prospective cohort study of women enrolled in 
the Women’s Interagency Health Study between 1998 and 2004, only 53% of participants were 
taking a guideline-consistent regimen and these women also had poorer immunologic and 
virologic outcomes than those who did receive guideline recommended treatment.13  
Many studies have documented the low rate of guideline recommended treatment in the African 
American Population. 13,30,32 However, some studies at public institutions have found an inverse 
or null association. A study in US Veterans found that being black was significantly associated 
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with receiving appropriate regimens.16 In 1999, a study of Ryan White-funded Facilities found 
no difference in prescribing trends between age, race, or sex.17 This research also demonstrates 
that commercially insured black patients were equally as likely to receive care from 2007 to 
2009 as their white counterparts. 
We found that patients with at least a high school education were less likely to receive guideline 
recommended treatment. This finding is not supported by the current literature which suggests 
that patients of lower socioeconomic status, often measured by a low level of education, have 
poorer HIV outcomes.34,35 Our findings may be a reflection of the data source and selection, as 
all patients included in the study qualify for commercial insurance through an employer or 
through a spouse that is employed. Therefore, patients of very low-socioeconomic status are 
likely not represented in this data source and the relationship between education and receipt of 
guideline recommended treatment that we observed reveals a different aspect of health services 
access in the US.  
Patients with a Charlson comorbidity index score of > 1 were less likely to receive guideline 
recommended treatment. This is in accordance with observations from studies of patients with 
HIV and other conditions and may be a reflection of the challenge in coordinating medical care, 
prescribing based on drug-drug interactions or patient preference.36-39  
Finally, as HIV patients are increasingly treated by providers that are not necessarily infectious 
disease experts, our results support a need for increased communication and dissemination of up 
to date information regarding HIV treatment guidelines to all health care providers. Historically, 
physician specialization effects have been studied through direct physician surveys. In 2001, 
Stone et al. surveyed 2478 internal medicine and ID physicians, with two theoretical patient 
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cases and found that specialty was significantly correlated with guideline recommended 
therapy.40  In 2003, a survey of physicians found that self-described ID specialists and expert-
generalists were more likely to comply with prescribing guidelines than non-expert generalists.41  
A 2011 Cochrane review of 4 US studies concluded that patients who saw ID specialists or 
physicians who saw a larger number of HIV patients were more likely to receive HAART. They 
also noted a trend for improved clinical outcomes among HIV patients who saw ID specialists 
compared to patients who did not see ID specialists.42  In our analysis, patients who saw ID 
specialists were more likely to receive guideline recommended initial cART regimens. However, 
it is important to note that our analysis reflects whether or not a patient fills a prescription for 
appropriate cART regimens through insurance and does not contain any information about 
prescriptions that were left unfilled. It is possible that patients who seek care from ID specialists 
are more involved in their own care. Another explanation could be a difference in counseling on 
cART regimens after office visits.  Furthermore, this analysis does not account for the 
physician’s HIV patient load nor measures physician knowledge, both which have been shown to 
be associated with guideline-recommended treatment. 
Limitations of this study are due to the nature of working with an administrative data set. No 
clinical data such as CD4 count or HIV viral load were included in this analysis to demonstrate 
appropriateness of therapy. Also, since this data contained only claims for prescriptions filled 
through insurance, no out-of-pocket drug expenses were accounted for. Nevertheless, the 
expensive nature of antiretroviral medications, it may be assumed that the number of missing 
“out-of-pocket” ARV medications is small. Furthermore, this analysis does not examine 
mortality or other health outcomes for commercially-insured patients taking guidelines-
recommended or non-guideline-recommended regimens. However, since the DHHS guidelines 
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are written using primary literature to support improved outcomes for patients, this may be 
inferred.  
CONCLUSION 
This study demonstrates continued disparities in receipt of ARV treatment in commercially 
insured patients between 2007 and 2009. It also emphasized the need for dissemination of 
information to all health care providers regarding HIV treatment. Future studies might be 
designed to elucidate the underlying causes for the difference in guideline adherence due to 
provider type. Studies linking commercial insurance data to medical records would be helpful in 
determining treatment patterns and outcomes in HIV patients. Continued monitoring and 
evaluation of health care delivery and treatment patterns is essential in order to reduce HIV 
associated morbidity and mortality within the general US population. 
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Table 1 : Regimen Categories   
Non-guideline 
recommended 
Monotherapy 1 antiretroviral medication 
Dual Therapy 2 antiretroviral medications 
Triple NRTI* 3 NRTIs* 
Other Multiple antiretroviral classes without 2 NRTI* 
base 
Guideline 
recommended 
NNRTI† 2 NRTIs* + 1 NNRTI† 
ISTI‡ 2 NRTIs* + 1 ISTI‡ 
PI§ 2 NRTIs† + 1 PI§ 
Boosted PI§ 2 NRTIs† + 1 Boosted PI§ 
Preferred Other 2 NRTIs† + Multiple antiretroviral medications 
*Nucleoside reverse transcriptase inhibitor 
†Non-nuceloside reverse transcriptase inhibitor 
‡Integrase strand transfer inhibitor 
§Protease inhibitor 
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Table 2: Characteristics of patients overall and according to type of initial antiretroviral regimen  
  All 
antiretroviral 
initiators 
(n=2115) 
 Guideline-
Recommended 
Treatment 
(n=1613) 
 Non-Guideline 
Recommended 
Treatment  
(n=502) 
 P-value  
  n (%)  n (%)  n (%)    
Patient Sex        <0.0001  
  Male  1835 (87)  1361 (84)  354 (71)    
  Female  475 (22)  252 (16)  148 (24)    
          
Patient Race        <0.0001  
  White  1243 (59)  990 (61)  253 (50)    
  Black  331 (16)  258 (16)  73 (15)    
  Hispanic  269 (13)  230 (14)  39 (8)    
  Other  272 (13)  135 (8)  137 (27)    
          
Age (median, IQR)   42 (35,49)  41 (35,48)  43 (35,52)  0.003*  
          
Education        0.0017  
  < High School  821 (39)  656 (41)  165 (33)    
  > High School  1294 (61)  957 (59)  337 (67)    
          
US Region          
  Northeast  314 (15)  228 (14)  86 (17)  0.0002  
  South  1204 (57)  938 (58)  266 (53)    
  Midwest  313 (15)  248 (15)  65 (13)    
  Rocky  97 (5)  79 (5)  18 (4)    
  Pacific  186 (9)  119 (7)  67 (13)    
          
ID Specialist        <0.0001  
  Yes  1072 (51)  942 (58)  130 (26)    
  No  1043 (49)  671 (42)  372 (74)    
          
Charlson Comorbidity Score        <0.0001  
  0  1619 (77)  1317 (82)  302 (60)    
  >1  496 (23)  296 (18)  200 (40)    
          
Year of cART initiation        0.0082  
  2007  409 (19)  320 (20)  89 (18)    
  2008  907 (43)  713 (44)  194 (39)    
  2009  799 (38)  580 (36)  219 (44)    
          
Healthcare Utilization† 
(median, IQR) 
 14 (7, 25)  14 (7,18)  15 (7, 30)  0.0154*  
          
*P-value determined by Mann-Whitney U test 
†Number of healthcare claims in the 180 days prior to first antiretroviral regimen 
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Table 3. Risk Ratios and Risk Differences associated with receiving guideline 
recommended regimens 
Characteristic  Risk Ratio (95% 
CI*) 
 Risk Difference (95% 
CI*) 
     
Sex     
  Male  1.24 (1.15, 1.33)  0.19 (0.14, 0.24) 
  Female  Ref  Ref 
     
Age (per 10 years)  0.97 (0.95, 0.99)  -0.03 (-0.04,- 0.01) 
     
Education     
  More than high School  0.91 (0.87, 0.96)  -0.08 (-0.12, -0.04) 
  High School or less  Ref  Ref 
     
Infectious Disease 
Specialist 
    
  Yes  1.37 (1.30, 1.43)  0.26 (0.23, 0.30) 
  No  Ref  Ref 
     
Charlson Comorbidity 
Index 
    
  Score of 0  Ref  Ref 
  Score > 1  0.75 (0.70,0.81)  -0.24 (-0.29, -0.20) 
     
*CI: Confidence Interval 
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Figure 1 Legend: 
Frequency of antiretroviral regimens stratified by whether patient had interaction with an 
infectious disease specialist or other type of physician (generalist). 
*PI: Protease inhibitor 
†NNRTI: Non-nucleoside reverse transcriptase inhibitor 
‡ISTI: Integrase strand transfer inhibitor 
§NRTI: Nucleoside/tide reverse transcriptase inhibitor 
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